Relief Therapeutics Will Release Mid/Late-Stage Study Results for COVID-19 Therapy

Relief Therapeutics plans to release topline results this month from a phase 2/3 trial evaluating an intravenous formulation of its COVID-19 treatment, RLF-100 (aviptadil).

The trial, which evaluated aviptadil in critical COVID-19 patients suffering from respiratory failure, is a collaboration between the company and NeuroRx.

NeuroRx has also launched a separate phase 2/3 trial to evaluate whether an inhaled formulation of aviptadil can reduce the likelihood of disease progression to critical COVID-19 with respiratory failure, if administered early.